Vorschau

PDF, Englisch - Hauptdokument Download (6MB) | Nutzungsbedingungen

Abstract

Primary liver cancer (PLC) is among the five deadliest cancers worldwide, which represents a clinical challenge to the global health system. Anatomically arising from a regenerative organ with high capacity for plasticity as the liver, hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) are the most frequent types of PLC. Although iCCA represents just 10-20% of liver tumors, the rise in its incidence in the past decades urges to develop new strategies that facilitate patient stratification and offer the best particular therapies and outcomes. Due to the limited treatment options and the considerable heterogeneity that this malignancy displays on distinct levels, integrative analyses have been key to identify targetable alterations that may improve the clinical management of this disease. Notably, gain-of-function mutations in the IDH1 gene, which lead to the accumulation of the oncometabolite 2-HG, have been commonly reported in 15-20% of iCCA cases. Mutant-IDH1 plays a pivotal role in the deregulation of homeostatic processes, strongly affecting the tumor immune microenvironment (TIME) and promoting cancer development. Nevertheless, further research is needed to decipher the intra- tumor heterogeneity and the molecular underpinnings by which mutant-IDH1 enhances cholangiocarcinogenesis.